Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:12:39.531Z.
Calculation as of: 2026-10-06T19:12:39.531Z.
Quote observation: 2026-10-06T19:03:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c421eb3f9cbf80487861bd205397d7cf152d6c676755a2868786c2d5add3cf98
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
MBody AI Ltd.
Market Cap
$3.25M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| MBody AI Ltd. (MBAI) | $3.25M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.26M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.20M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.12M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.40M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.01M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.49M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $2.95M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
